HOWL stock news · Werewolf Therapeutics Inc
Get alerts for HOWL
Follow Werewolf Therapeutics Inc (HOWL) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HOWLUS Composite PMI Soars in August; Gold Prices Climb.
Good for HOWLShares increased 113% after announcing a merger with Ambros Therapeutics.
Werewolf Therapeutics targets the unexploited pain management sector through its agreement with Ambros.
NeutralThe merger between Werewolf Therapeutics and Ambros Therapeutics marks a strategic move to tap into the pain management market, particularly for Complex Regional Pain Syndrome Type 1. The $150 million private placement will support the combined company's operations and drug development efforts, positioning them favorably in a market with significant unmet needs.
A $500M merger narrative has emerged involving one of Israel Englander's biotech selections.
NeutralWerewolf Therapeutics has announced a merger with Ambros Therapeutics, valuing the latter at $500 million and resulting in a substantial pre-market rally of approximately 75% for Werewolf's shares. This merger not only enhances Werewolf's market position but also secures additional funding for drug development, indicating strong future growth potential.
Werewolf Therapeutics (HOWL) shares surge nearly 90% in after-hours trading following a $28 million agreement with EMD Serono.
NeutralWerewolf Therapeutics' stock skyrocketed nearly 90% after hours following the announcement of a deal to sell its pre-clinical technology platforms to EMD Serono for $28 million upfront, plus additional payments. This transaction not only provides Werewolf with non-dilutive cash but also allows it to retain rights to its clinical-stage programs, marking a pivotal moment for the company.
Werewolf Therapeutics, Inc. enters into a significant definitive agreement (HOWL).
NeutralWerewolf Therapeutics, Inc. has filed a Form 8-K announcing its entry into a material definitive agreement, which is likely to have a positive impact on its operations and investor sentiment. Such agreements often signal growth opportunities or strategic partnerships that can enhance the company's value.